One of the most promising aspects of molecular imaging is its potential capacity to measure therapy effects long before morphologic changes are detected. The most frequently used PET tracer in oncology remains 18F-FDG. However, despite its high sensitivity, this tracer has some major drawbacks, of
No takes yet. Share an insight, caveat, or question.
Saint‐Hubert et al. (2010) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: